Sunday, November 20, 2011

Cancer Doctors Still Not Great With Patients' Pain (HealthDay)

THURSDAY, Nov. 17 (HealthDay News) -- Oncologists think they are good at managing cancer patients' pain, but a new survey shows otherwise.

In response to two hypothetical vignettes describing a cancer patient who was suffering from pain, the majority of oncologists offered up a treatment plan that pain specialists would consider "unacceptable."

"There are serious deficiencies in oncologists' knowledge of cancer pain management," said study author Brenda Breuer, director of epidemiologic research in the department of pain medicine and palliative care at Beth Israel Medical Center in New York City.

The study appears in the Nov. 14 issue of the Journal of Clinical Oncology.

Depending on the type of cancer and how advanced it is, anywhere from 14 percent to 100 percent of cancer patients experience pain, according to background information in the study.

In recent years, there's been a growing understanding among cancer experts about the importance of both properly assessing and treating pain, and better techniques for doing so, said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.

Despite talk about a greater understanding of the importance of treating pain, oncologists' attitudes toward pain management have "demonstrated disturbingly little progress" since 1990, when a similar survey was conducted, according to an accompanying journal editorial.

"The entire issue of pain management for patients with cancer has been a priority concern for many experts and organizations, particularly over the past several years," Lichtenfeld said. "We have begun to recognize that we are not managing pain adequately and this report and editorial go directly to the heart of the matter. Doctors think they are managing pain properly, but the results of the report suggest otherwise."

Under-treating pain can occur for multiple reasons, experts said. Some patients are reluctant to complain too much, Breuer said. "They don't want to be 'bad' patients, or they just think pain goes with the territory and don't realize there may be help for them," she said.

Others put their trust in their oncologist and don't realize he or she may not know all there is to know about treating pain, Breuer said.

In some cases, oncologists may be focused on treating the disease and not ask enough questions about a patient's pain, Lichtenfeld said.

In the study, researchers surveyed more than 600 U.S. oncologists about their knowledge, attitudes and practices related to pain management. Oncologists tended to rate themselves as less conservative than their peers in administering pain medications.

According to the oncologists, barriers to proper pain management include patient reluctance to report pain; patient reluctance to take opioids because of addiction fears or fears of adverse reactions; excessive regulation of opioids; inadequate assessment of patients' pain by doctors and nurses and patient inability to pay for services or pain medications.

In one hypothetical scenario, oncologists were asked whether it was a good idea to increase the dosage of morphine for a man with lung cancer who was experiencing pain despite already being on a relatively high dose of morphine.

The correct answer is "no," because the increase in dosage suggested was unnecessarily high. Even so, 31 percent of oncologists thought it would be a good idea. While the rest knew it wasn't a good idea, only 13 percent chose both the right answer and the right reason for avoiding such a large increase, which was the risk of side effects such as excessive sleepiness and "mental clouding."

Wrong reasons cited for not giving the higher dose included causing a dangerous decrease in respiration; because the higher dose could lead to increasing tolerance and the medication to become less effective over time; and because of a "regulatory climate that puts doctors under scrutiny if relatively high doses are prescribed."

The study also found that few oncologists (16 percent) said they frequently made referrals to pain or palliative medicine care specialists, who specialize in treating people at the end of life, Breuer said.

"Patients need to know that there is such a thing as pain medicine and palliative care specialists. These are recognized specialities that you get board certification in. Patients can ask for consults. That is the best advice I can give them," she said.

More information

The American Cancer Society has more on pain control for cancer patients.

Source: http://us.rd.yahoo.com/dailynews/rss/cancer/*http%3A//news.yahoo.com/s/hsn/20111118/hl_hsn/cancerdoctorsstillnotgreatwithpatientspain

andrew luck andrew luck day light savings time 2011 hocus pocus hocus pocus bj penn roasted pumpkin seeds

Google Music vs Amazon MP3 vs iTunes: Which Online Music Store Is the Best for You? [Lifehacker]

Google opened its new music store to all comers in the US this week, touting its partnerships with music labels and indie musicians, and its broad reach thanks to the Android Market. The new store has millions of songs for sale, but whether it's a game changer, serious competition for iTunes and Amazon MP3, or the best online music store out there is another question entirely. Let's take a look at each service based on its features. More »


Source: http://feeds.gawker.com/~r/gizmodo/full/~3/RqEteKBqCdA/google-music-vs-amazon-mp3-vs-itunes-which-online-music-store-is-the-best-for-you

imessage imessage sukkot sukkot chia seeds aziz ansari aziz ansari

Saturday, November 19, 2011

Breast cancer drug revoked for 'life-threatening' risks

The blockbuster drug Avastin should no longer be used in advanced breast cancer patients because there's no proof that it extends their lives and it presents dangerous side effects, the government declared Friday.

  1. Don't miss these Health stories

    1. Heavy shopping bags weigh on your psyche

      Researchers have found that when we are physically weighed down, with anything from groceries to gifts, our thoughts inescapably turn to serious -- weighty -- subjects.

    2. The economy may be killing your sex life
    3. You can't help loving (or hating) 'Twilight,' study finds
    4. Fertility math? Most women flunk, survey finds
    5. Kotex tampons recalled over contamination

The ruling by the Food and Drug Administration was long expected, but it was certain to disappoint women who say they've run out of other options as their breast cancer spread through their bodies. Impassioned patients had lobbied furiously to preserve Avastin as a last shot.

"This was a difficult decision," said FDA Commissioner Margaret Hamburg. But, she added that "it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks."

Opinion: Don't deny access to last-ditch drug

Those risks include severe high blood pressure, massive bleeding, heart attack or heart failure, and perforations in parts of the body such as the stomach and intestines, she said.

Avastin is the world's best-selling cancer drug, and also is used to treat certain forms of colon, lung, kidney and brain cancers. So even though FDA formally revoked its approval of the drug to treat breast cancer, doctors still could prescribe it ? but insurers may not pay for it. Including infusion fees, a year's treatment with Avastin can cost $100,000.

Some insurers already had quit covering the drug's use in breast cancer after FDA's advisers twice, once last year and once last summer, urged revoking the approval.

But Medicare said Friday that it will keep paying for now.

"Medicare will continue to cover Avastin," Don McLeod, spokesman for the Centers for Medicare and Medicaid, or CMS, said on Friday.

"CMS will monitor the issue and evaluate coverage options as a result of action by the FDA but has no immediate plans to change coverage policies."

Survey: Is your child spoiled by the holidays?

The statement from the U.S. healthcare program could mitigate concerns that patients using the drug would lose insurance coverage should the FDA revoke approval for its use in breast cancer.

"We are disappointed with this outcome," said Charlotte Arnold, a spokeswoman for Genentech, a unit of Roche. "We remain committed to the many women with this incurable disease and will continue to provide help through our patient support programs to those who may be facing obstacles to receiving their treatment."

She said Roche will pursue a new Phase III study of Avastin in combination with the chemotherapy drug paclitaxel in previously untreated metastatic breast cancer.

The FDA's decision could prompt a review of industry guidelines from groups like the National Comprehensive Cancer Network, which represents leading cancer treatment centers.

NCCN has so far not strayed from its earlier guideline, approving use of Avastin with paclitaxel for some patients.

One patient advocacy group called the decision a mistake.

"Any one life is significant. In this case we're talking about several thousand lives a year," said Frank Burroughs of the Abigail Alliance, which advocates for access to experimental medicine.

In 2008, the FDA allowed Avastin to be marketed as a treatment for breast cancer that has spread, or metastasized, to other parts of the body and is generally considered incurable. The approval came under a special program that allows patients access to promising treatments while their makers finish the studies needed for final proof that they really work as promised.

The Associated Press and Reuters contributed to this report

Source: http://www.msnbc.msn.com/id/45355965/ns/health-cancer/

move your money alabama vs lsu alabama vs lsu robert schuller guy fawkes day jesse ventura ohio state football

Wednesday, November 16, 2011

iTunes Match goes live, better late than never

iTunes Match officially launches this week. Is it worth the $24.99 a year??

Back in June, former Apple CEO Steve Jobs introduced a service called iTunes Match, which was described as a kind of central music repository, or digital locker. It works like this: A user pays Apple a yearly fee of $24.99. The company scans the user's library, including tracks uploaded from CDs or purchased from services other than iTunes, and locates "matches." Each match is added to an iCloud account, which the user can dip into at any time from any computer.?

Skip to next paragraph

So let's say you've got a gigantic CD collection. You've uploaded the contents of 400 CDs to your iTunes account, but all those thousands of tracks don't appear on your smartphone, or your tablet. Providing Apple has the tracks in its library, with Match, you'll be able to access your music from anywhere (Wi-Fi or 3G connection permitting, of course).?

Match can be extended to 10 devices; the music, Apple says, plays back at "256-Kbps AAC DRM-free quality ? even if your original copy was of lower quality." In other words, your crummy early MP3 collection will sound crisp and clear.

"This takes minutes, not weeks," Jobs said this summer, according to Computerworld.?"If you have to upload your entire library to some service in the cloud, that could take weeks," he added. Match was scheduled to hit back in October. But because of unspecified delays ? possibly something to do with licensing issues ? iTunes Match didn't arrive until this week.?

As Hayley Tsukayama of the Washington Point reports today, the launch didn't go off without a couple hiccups ? servers seemed to be a little jammed, and some users had trouble getting Match up and started. "[T]he problem," Tsukayama notes, "seems to have largely gone away about an hour after the download went live."?

So should you sign up for Match? Over at Lifehacker.com, Adam Dachis offers a run-down.?

"If you're into all things Apple, iTunes Match is likely the best service for you. It's cheap, it keeps your music backed up and synced without the need to upload your entire collection (or possibly any of it), and it'll work with all of your devices," Dachis writes. "If you're not fully entrenched in the Apple ecosystem, iTunes Match might not be your ideal service. If you need your music on an Android device, for example, you're out of luck."?

For more tech news, sign up for the?BizTech newsletter, which ships via e-mail each Wednesday.

Source: http://rss.csmonitor.com/~r/feeds/csm/~3/fTjo6sPeV1k/iTunes-Match-goes-live-better-late-than-never

oklahoma fall back time change when does daylight savings start when does daylight savings start earthquake in texas earthquake in texas